Evidence map›Paper›PMID 29122934›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response.

Nai-Kong Cheung, Katharine C Hsu

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Nai-Kong CheungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. cheungn@mskcc.org.
Katharine C HsuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Neuroblastoma with armed T cellsR01CA182526 · NCI · WAYNE STATE UNIVERSITY · PI CHEUNG, NAI-KONG V, LUM, LAWRENCE G · 2014 to 2019
$3.9M
Combination immunotherapy for neuroblastoma: model of innate tumor immunityR01CA164365 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C, MODAK, SHAKEEL · 2012 to 2014
$1.1M
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastomaR01FD005415 · FDA · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C, MODAK, SHAKEEL · 2016 to 2019
$750k
FDA HHS R01 FD005415NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA164365NCI NIH HHS R01 CA182526
6 · The paper itself

Abstract

Immune checkpoints have been a focus of immunotherapy in the recent decade. Killer cell immunoglobulin-like receptors (KIR) and their cognate human leukocyte antigen (HLA) class I ligands have evolved as checkpoints to ensure self-tolerance of natural killer cells. Both KIR and HLA genetic profiles are potential biomarkers of immunotherapy outcome.

Indexed as

GenotypeNeuroblastomaAntibodies, MonoclonalBiomarkersChildHLA-C AntigensHumansImmunotherapyKiller Cells, NaturalLigandsReceptors, KIRAntibodies, MonoclonalBiomarkersdinutuximabHLA-C AntigensLigandsReceptors, KIR

Identifiers

PMID29122934
PMCPMC5754255

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.